Numerous reports suggest that
IL-6 promotes survival and proliferation of
multiple myeloma (MM) cells through the phosphorylation of a cell signaling
protein, STAT3. Thus, agents that suppress STAT3 phosphorylation have potential for the treatment of MM. In the present report, we demonstrate that
curcumin (
diferuloylmethane), a pharmacologically safe agent in humans, inhibited IL-6-induced STAT3 phosphorylation and consequent STAT3 nuclear translocation.
Curcumin had no effect on STAT5 phosphorylation, but inhibited the IFN-alpha-induced STAT1 phosphorylation. The constitutive phosphorylation of STAT3 found in certain MM cells was also abrogated by treatment with
curcumin.
Curcumin-induced inhibition of STAT3 phosphorylation was reversible. Compared with
AG490, a well-characterized
Janus kinase 2 inhibitor,
curcumin was a more rapid (30 min vs 8 h) and more potent (10 micro M vs 100 micro M) inhibitor of STAT3 phosphorylation. In a similar manner, the dose of
curcumin completely suppressed proliferation of MM cells; the same dose of
AG490 had no effect. In contrast, a cell-permeable STAT3 inhibitor
peptide that can inhibit the STAT3 phosphorylation mediated by Src blocked the constitutive phosphorylation of STAT3 and also suppressed the growth of myeloma cells.
TNF-alpha and
lymphotoxin also induced the proliferation of MM cells, but through a mechanism independent of STAT3 phosphorylation. In addition,
dexamethasone-resistant MM cells were found to be sensitive to
curcumin. Overall, our results demonstrated that
curcumin was a potent inhibitor of STAT3 phosphorylation, and this plays a role in the suppression of MM proliferation.